Navigation Links
AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
Date:12/10/2013

i>
  • ABT-333
  • 12 weeksPEARL-III

    GT1b, treatment-naive

    (400 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267
  • ABT-333
  • Placebo
  • 12 weeksPEARL-IV

    GT1a, treatment-naive

    (300 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267
  • ABT-333
  • Placebo
  • 12 weeksTURQUOISE-II

    GT1, treatment-naive and treatment-experienced (with compensated cirrhosis)

    (380 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 24 weeksa projected study population

    b ABT-450/ritonavir

    c ABT-267 is co-formulated with ABT-450/r, administered as two pills once daily

    The 3D regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. The combination of three different mechanisms of action interrupts the HCV replication process with the goal of optimizing SVR rates across different patient populations. In May of 2013, AbbVie's investigational 3D regimen with and without ribavirin for HCV GT1 was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).

    ABT-450 was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors. ABT-450 is being developed by AbbVie for use in combination with AbbVie's other investigational medicines for the treatment of HCV.

    Safety Information for Ribavirin and RitonavirRibavirin and ritonavir are not approved for the investigational use discussed above, and no conclusions can or should be drawn regarding the safety or ef
    '/>"/>

    SOURCE AbbVie Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AbbVie Named to S&P 500 Dividend Aristocrat Index
    2. AbbVie Issues Inaugural Full-Year Outlook for 2013
    3. AbbVie to Present at Barclays Global Health Care Conference
    4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
    5. AbbVie to Host First-Quarter Earnings Conference Call
    6. AbbVie Reports First-Quarter 2013 Financial Results
    7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
    8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
    9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
    10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
    11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... , Aug. 22, 2014 Today, ... that modify the religious "accommodation" but still require ... that have an abortifacient effect, including Plan B ... after pill"). The Obama Administration also announced that ... closely held, for-profit corporations. The regulations ...
    (Date:8/22/2014)... Aug. 22, 2014  Dr. Mark Rasak , ... Diamond Lifetime Achievement Award in the field of Medicine ... Cardiovascular Clinical Associates. Dr. Rasak has over ... major aspects of the business; overseeing the daily operations; ... coronary intervention. In addition, he is an honored Fellow ...
    (Date:8/22/2014)... Cali ., Aug. 22, 2014  Research ... shows that a therapy being developed by Hera Therapeutics Inc. ... cause 70 percent of all cervical cancer. When ... replication of HPV-16, HPV-18 and HPV-11 cells, according to ... Ph.D., who presented the findings at the Seattle ...
    Breaking Medicine Technology:Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
    ... At its regularly scheduled meeting on September 14, ... (the "Company" or "AMPAC") (Nasdaq: APFC ) ... that shareholders at the next Annual Meeting amend AMPAC,s ... for director election with a simple majority vote requirement. ...
    ... U.S. Food and Drug Administration (FDA), working in close ... announced that Forest Pharmaceuticals, Inc. entered into a plea ... actions including distribution of an unapproved new drug, distribution ... inspection. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
    Cached Medicine Technology:American Pacific Adopts Corporate Governance Changes 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3
    (Date:8/23/2014)... 23, 2014 Legal Insider Bot ... by Greg Marks has been generating a buzz of ... The commotion surrounding the new product has drawn the ... , “In recent years the market has ... commonly referred to as robots or ‘bots,'” reports Hendricks. ...
    (Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
    (Date:8/23/2014)... August 23, 2014 Professional kitchen employees, ... study aid in preparing for Food Safety Certification exams ... by Dynamic Path. , Dynamic Path announced the ... includes more than 200 review questions for culinary industry ... designed to cover requirements of the ServSafe® Food Safety ...
    (Date:8/23/2014)... (PRWEB) August 23, 2014 Young adults in Athens, ... doing drugs should pick up the phone and call the new ... teen drug addict . , Troubled Teen Athens is a ... ready to finally take the necessary steps to end substance abuse ... are quick to go to friends or peers when really they ...
    (Date:8/23/2014)... 23, 2014 Youth substance abuse is ... no different in Houston, TX. Substance abuse can happen ... to drug and alcohol dependency in higher numbers than ... beat substance abuse, but don’t know where to find ... can be a challenge because most treatment options are ...
    Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
    ... of the population but account for nearly 20 percent ... major risk factor for // suicide in the elderly. ... thoughts in depressed elderly patients. ,Researchers from ... 600 elderly patients with depression. Some patients were assigned ...
    ... skin’s worst enemies, but now some dermatologists are taking cues from sunlight ... phototherapy. ,Standing in front of a UV light is ... from a disease called morphea , it can affect any area of ... joints, also known as localized scleroderma. She says: “I had a bunch ...
    ... can be a significant predictor of breast cancer risk for ... ,In 1992, researchers sampled nearly 62,000 women, ages ... age 18 and their current weight. Since then, the women ... in addition to any diagnosis of cancer. Research shows ...
    ... Around 165,000 cases of lung cancer are diagnosed in ... to 25 percent are classified // as small cell ... and the disease frequently travels to the brain and ... cancer, for example, ranges up to 80 percent. Whether ...
    ... a new drug is showing promising results.For the past ... recombinant immunotoxins. An immunotoxin is bioengineered and consists of ... antibodies that are commonly used to fight leukemia. One ... a phase II study. ,Researchers say in a ...
    ... A recent study has shown that a chemotherapy regimen ... prednisone is effective in the treatment of hormone-refractory prostate ... to symptomatic patients earlier in their disease. ... study of this treatment regimen is planned. From a ...
    Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
    Sterile cordless eraser tips, packsize is 10/box....
    Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
    Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium....
    45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
    Medicine Products: